title: [New institute for additional drug evaluation. Do we really need another barrier?].
authors.forename: Klaus
authors.initials: K
authors.lastname: Schmidt
mesh_terms: D003363:Cost Control / Q000331:legislation & jurisprudence; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D005858:Germany; D018166:Health Care Reform / Q000191:economics* / Q000331:legislation & jurisprudence; D006801:Humans; D009313:National Health Programs / Q000191:economics* / Q000331:legislation & jurisprudence; D011358:Product Surveillance, Postmarketing; D011786:Quality Control
vernacular_title: Neues Institut soll Arzneimittel zusätzlich prüfen. Brauchen wir wirklich noch einen Sperrzaun?